Prosecution Insights
Last updated: October 17, 2026
Application No. 18/729,020

LIPIDIC COMPOUNDS, AND USES THEREOF

Final Rejection §102§112
Filed
Jul 15, 2024
Priority
Jan 17, 2022 — EU 22305043.6 +1 more
Examiner
PIPIC, ALMA
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sanofi S.A.
OA Round
2 (Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
10m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
394 granted / 722 resolved
-5.4% vs TC avg
Strong +55% interview lift
Without
With
+54.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
48 currently pending
Career history
775
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
44.0%
+4.0% vs TC avg
§102
7.6%
-32.4% vs TC avg
§112
31.6%
-8.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 722 resolved cases

Office Action

§102 §112
*DETAILED ACTION* Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' response dated September 10, 2026 is acknowledged. Priority This application is a 371 of PCT/EP2023/050891 filed on 01/16/2023, which claims foreign priority in EP22305043.6 filed on 01/17/2022. Claim Status Claims 1, 4-10, 12-17, 32, and 33 are pending. Claims 2, 3, 11, 13-16, and 18-31 were cancelled. Claims 6, 9, 14-16 and 32 are withdrawn. Claim 1 was amended. Claims 1, 4, 5, 7, 8, 10, 12, 13, 17, and 33 are examined. Election/Restriction The search was extended to the remaining species of compounds of formula I in claims 1, 4, 5, 7, 8, 10, 12, 13, and 17. Withdrawn Claim Rejections - 35 USC § 112 Rejections of claims 1, 3-5, 7, 8, 10, 12, 13, and 17 are withdrawn because claim 1 was amended to overcome the grounds of rejection and claim 3 was canceled. Withdrawn Claim Rejections - 35 USC § 102 Rejections of claims 1, 4, 5, 7, 8, 10, 12, and 13 as being anticipated by Acosta (WO 2014/105764 Al Published July 3, 2014 – of record in IDS dated 04/30/2025) are withdrawn because claim 1 was amended by deleting the R1 variable that is met by Acosta. New Claim Rejections – 35 USC § 112 Necessitated by Amendment The following is a quotation of 35 U.S.C. l 12(b): (b) CONCLUSION.-The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claims 1, 4, 5, 7, 8, 10, 12, 13, and 17 are rejected under 35 U.S.C. l 12(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 was amended to require the limitations of claim 3, and further recites that each of R1a to R1jj is bonded to Z through the open valance depicted therein. The claim is indefinite because none of the structures indicate a point of attachment of the R1 variable to Z. For the purpose of searching and applying prior art, the point of attachment of the compounds R1a to R1jj to Z is interpreted and given the meaning consistent with the specification and claim 17. In the remarks dated September 10, 2026, applicant stated that the R1 groups of present claim 1 are expressly defined as being bonded to Z through the open valance depicted therein on the lefthand side of each of the structures, such that the point of attachment of each R1 group is unambiguous. The argument is not persuasive because an open valance is not depicted in any of the recited structures and a person skilled in the art cannot readily determine how each structure is attached to the Z variable. A claim is required to be definite and complete in itself. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). The examiner acknowledges that the specification teaches species of compounds of formula I from which it is apparent how the R1 variable attaches to the Z variable, however the claim has to be clear on its own and currently the point of attachment on the R1 variable is unknown. Grounds of rejection may be obviated by amending each structure by placing a dotted or a squiggly line through a bond at which the attachment between R1 and Z occurs. For example: PNG media_image1.png 166 272 media_image1.png Greyscale wherein PNG media_image2.png 40 37 media_image2.png Greyscale represents a bond which covalently bonds the R1 variable to the Z variable. Alternatively, ground of rejection may be obviated by placing an asterisk near the atom to which the Z variable is covalently bonded. For example: PNG media_image3.png 171 240 media_image3.png Greyscale wherein * represents the point at which the Z variable covalently bonds to the R1 variable. Claims 4, 5, 7, 8, 10, 12, 13, and 17 are rejected as indefinite because the claims depend from an indefinite base claim and contain indefinite limitations. Conclusion Claim 33 is allowed. Claims 1, 4, 5, 7, 8, 10, 12, 13, and 17 are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alma - Pipic whose telephone number is (571)270-7459. The examiner can normally be reached M-F 9:00am-5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALMA PIPIC/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Jul 15, 2024
Application Filed
Jun 10, 2026
Non-Final Rejection mailed — §102, §112
Sep 10, 2026
Response Filed
Sep 24, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12745771
METHODS OF CONTROLLING OR PREVENTING INFESTATION OF SOYBEAN PLANTS BY PHYTOPATHOGENIC MICROORGANISMS
5y 2m to grant Granted Sep 29, 2026
Patent 12740942
SURFACE TREATMENT OF CONTACT LENS AND TREATMENT OF OCULAR DISCOMFORT BY WATER SOLUBLE POLYMERS AND LIPIDS/LIPOSOMES
2y 7m to grant Granted Sep 22, 2026
Patent 12728006
BIOCOMPATIBLE STRUCTURE, AND FABRICATING METHODS AND APPLICATIONS OF SAME
4y 0m to grant Granted Sep 08, 2026
Patent 12691066
DUAL-TARGETING BIOMIMETIC LIPOSOME WITH ELEMENE (ELE) AND CABAZITAXEL (CTX), AND PREPARATION METHOD AND USE THEREOF
2y 5m to grant Granted Jul 28, 2026
Patent 12679785
Microbe-Based Products for Enhancing Plant Root and Immune Health
3y 11m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+54.7%)
3y 1m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 722 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month